Trial Profile
A Randomized, Placebo-Controlled, Double-Blind Six Month Study Followed by an Open-Label Extension Phase to Evaluate the Efficacy, Safety and Tolerability of MN-001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2022
Price :
$35
*
At a glance
- Drugs Tipelukast (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors MediciNova
- 19 May 2021 Status changed from active, no longer recruiting to completed, as per results presented at the 117th International Conference of the American Thoracic Society.
- 19 May 2021 Results assessing safety, tolerability and efficacy of MN-001 in idiopathic pulmonary fibrosis, presented at the 117th International Conference of the American Thoracic Society.
- 02 Jun 2020 Status changed from recruiting to active, no longer recruiting.